Analysts Set Expectations for XFOR FY2030 Earnings

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Equities researchers at Brookline Capital Markets boosted their FY2030 earnings estimates for shares of X4 Pharmaceuticals in a report issued on Wednesday, November 4th. Brookline Capital Markets analyst L. Cann now forecasts that the company will earn $3.19 per share for the year, up from their prior forecast of $2.86. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share.

Separately, Weiss Ratings upgraded X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, November 3rd. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $11.25.

X4 Pharmaceuticals Stock Performance

X4 Pharmaceuticals stock opened at $3.33 on Monday. X4 Pharmaceuticals has a twelve month low of $2.43 and a twelve month high of $4.83. The stock’s fifty day simple moving average is $3.22 and its 200-day simple moving average is $3.78. The company has a quick ratio of 11.02, a current ratio of 11.30 and a debt-to-equity ratio of 0.49.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.01. The company had revenue of $2.88 million during the quarter, compared to analysts’ expectations of $2.78 million. X4 Pharmaceuticals had a negative net margin of 474.74% and a negative return on equity of 47.35%.

Insider Transactions at X4 Pharmaceuticals

In related news, President John Volpone sold 24,576 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $4.44, for a total value of $109,117.44. Following the sale, the president owned 265,305 shares of the company’s stock, valued at $1,177,954.20. This trade represents a 8.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Adam R. Craig sold 47,436 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $4.44, for a total transaction of $210,615.84. Following the completion of the sale, the chairman directly owned 328,651 shares in the company, valued at approximately $1,459,210.44. This trade represents a 12.61% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 83,779 shares of company stock valued at $353,387. 1.13% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. raised its holdings in shares of X4 Pharmaceuticals by 2,871.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 213,258 shares of the company’s stock valued at $618,000 after purchasing an additional 206,080 shares in the last quarter. Alps Advisors Inc. lifted its position in shares of X4 Pharmaceuticals by 36.2% during the 3rd quarter. Alps Advisors Inc. now owns 130,424 shares of the company’s stock worth $378,000 after purchasing an additional 34,698 shares during the last quarter. WINTON GROUP Ltd lifted its position in shares of X4 Pharmaceuticals by 35.8% during the 2nd quarter. WINTON GROUP Ltd now owns 14,400 shares of the company’s stock worth $67,000 after purchasing an additional 3,800 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in shares of X4 Pharmaceuticals during the 2nd quarter worth $313,000. Finally, AXQ Capital LP acquired a new position in shares of X4 Pharmaceuticals during the second quarter worth $107,000. Institutional investors and hedge funds own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing therapies for rare diseases caused by disorders of the immune system. The company’s research centers on the CXCR4 pathway, which plays a role in the movement and function of immune cells.

X4’s lead product, XOLREMDI (mavorixafor), is an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration for use in patients aged 12 and older with WHIM syndrome, a rare primary immunodeficiency disorder.